APO Research
Talk to an analyst

APO RESEARCH · REPORT

Montelukast Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Montelukast Drug Market Outlook and Growth Opportunities 2026

20 December 2025212 pages

Choose your research edition.

Industry ResearchMontelukast Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Montelukast Drug Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Montelukast Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Montelukast Drug Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal Montelukast Drug Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Montelukast Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Montelukast Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Montelukast Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Montelukast Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Montelukast Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Montelukast Drug market include Teva, Sandoz, Merck & Co., Mylan, Unimark, Unichem Laboratories, Torrent Pharmaceuticals, Shanghai Anbison Lab and Perrigo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Montelukast Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Montelukast Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Montelukast Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Montelukast Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Montelukast Drug Segment by Company

Teva

Sandoz

Merck & Co.

Mylan

Unimark

Unichem Laboratories

Torrent Pharmaceuticals

Shanghai Anbison Lab

Perrigo

MACLEODS

Lannett Company

Jubilant Pharma

Hikma Group

Hetero

Glenmark Pharmaceuticals

Dr. Reddys Laboratories

CSPC Ouyi Pharmaceutical

Cipla

Aurobindo Pharma

Apotex

Amneal Pharmaceuticals

Ajanta Pharma

Accord Healthcare

Montelukast Drug Segment by Type

Tablets

Oral Granules

Montelukast Drug Segment by Application

Hospital

Drug Store

Others

Montelukast Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Montelukast Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Montelukast Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Montelukast Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Montelukast Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Montelukast Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Montelukast Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Montelukast Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Montelukast Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Montelukast Drug industry.

Chapter 3: Detailed analysis of Montelukast Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Montelukast Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Montelukast Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Montelukast Drug Industry Trends Table 2. Montelukast Drug Industry Drivers Table 3. Montelukast Drug Industry Opportunities and Challenges Table 4. Montelukast Drug Industry Restraints Table 5. Global Montelukast Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Montelukast Drug Revenue Share by Company (2021-2026) Table 7. Global Montelukast Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Montelukast Drug Sales Volume Share by Company (2021-2026) Table 9. Global Montelukast Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Montelukast Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Montelukast Drug Key Company Manufacturing Base & Headquarters Table 12. Global Montelukast Drug Company, Product Type & Application Table 13. Global Montelukast Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Montelukast Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tablets Table 18. Significant Companies of Oral Granules Table 19. Global Montelukast Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Montelukast Drug Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Montelukast Drug Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Montelukast Drug Sales Volume Share by Type (2021-2026) Table 23. Global Montelukast Drug Sales Volume Share by Type (2027-2032) Table 24. Global Montelukast Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Montelukast Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Montelukast Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Montelukast Drug Sales Value Share by Type (2021-2026) Table 28. Global Montelukast Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Drug Store Table 31. Significant Companies of Others Table 32. Global Montelukast Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 33. Global Montelukast Drug Sales Volume by Application (2021-2026) & (W Units) Table 34. Global Montelukast Drug Sales Volume by Application (2027-2032) & (W Units) Table 35. Global Montelukast Drug Sales Volume Share by Application (2021-2026) Table 36. Global Montelukast Drug Sales Volume Share by Application (2027-2032) Table 37. Global Montelukast Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Montelukast Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Montelukast Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Montelukast Drug Sales Value Share by Application (2021-2026) Table 41. Global Montelukast Drug Sales Value Share by Application (2027-2032) Table 42. Global Montelukast Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 43. Global Montelukast Drug Sales by Region (2021-2026) & (W Units) Table 44. Global Montelukast Drug Sales Market Share by Region (2021-2026) Table 45. Global Montelukast Drug Sales by Region (2027-2032) & (W Units) Table 46. Global Montelukast Drug Sales Market Share by Region (2027-2032) Table 47. Global Montelukast Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Montelukast Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Montelukast Drug Sales Value Share by Region (2021-2026) Table 50. Global Montelukast Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Montelukast Drug Sales Value Share by Region (2027-2032) Table 52. Global Montelukast Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Montelukast Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Montelukast Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Global Montelukast Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Montelukast Drug Sales by Country (2021-2026) & (W Units) Table 57. Global Montelukast Drug Sales Market Share by Country (2021-2026) Table 58. Global Montelukast Drug Sales by Country (2027-2032) & (W Units) Table 59. Global Montelukast Drug Sales Market Share by Country (2027-2032) Table 60. Global Montelukast Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Montelukast Drug Sales Value Market Share by Country (2021-2026) Table 62. Global Montelukast Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Montelukast Drug Sales Value Market Share by Country (2027-2032) Table 64. Teva Company Information Table 65. Teva Business Overview Table 66. Teva Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Teva Montelukast Drug Product Portfolio Table 68. Teva Recent Development Table 69. Sandoz Company Information Table 70. Sandoz Business Overview Table 71. Sandoz Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Sandoz Montelukast Drug Product Portfolio Table 73. Sandoz Recent Development Table 74. Merck & Co. Company Information Table 75. Merck & Co. Business Overview Table 76. Merck & Co. Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Merck & Co. Montelukast Drug Product Portfolio Table 78. Merck & Co. Recent Development Table 79. Mylan Company Information Table 80. Mylan Business Overview Table 81. Mylan Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Mylan Montelukast Drug Product Portfolio Table 83. Mylan Recent Development Table 84. Unimark Company Information Table 85. Unimark Business Overview Table 86. Unimark Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Unimark Montelukast Drug Product Portfolio Table 88. Unimark Recent Development Table 89. Unichem Laboratories Company Information Table 90. Unichem Laboratories Business Overview Table 91. Unichem Laboratories Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Unichem Laboratories Montelukast Drug Product Portfolio Table 93. Unichem Laboratories Recent Development Table 94. Torrent Pharmaceuticals Company Information Table 95. Torrent Pharmaceuticals Business Overview Table 96. Torrent Pharmaceuticals Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Torrent Pharmaceuticals Montelukast Drug Product Portfolio Table 98. Torrent Pharmaceuticals Recent Development Table 99. Shanghai Anbison Lab Company Information Table 100. Shanghai Anbison Lab Business Overview Table 101. Shanghai Anbison Lab Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Shanghai Anbison Lab Montelukast Drug Product Portfolio Table 103. Shanghai Anbison Lab Recent Development Table 104. Perrigo Company Information Table 105. Perrigo Business Overview Table 106. Perrigo Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Perrigo Montelukast Drug Product Portfolio Table 108. Perrigo Recent Development Table 109. MACLEODS Company Information Table 110. MACLEODS Business Overview Table 111. MACLEODS Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. MACLEODS Montelukast Drug Product Portfolio Table 113. MACLEODS Recent Development Table 114. Lannett Company Company Information Table 115. Lannett Company Business Overview Table 116. Lannett Company Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Lannett Company Montelukast Drug Product Portfolio Table 118. Lannett Company Recent Development Table 119. Jubilant Pharma Company Information Table 120. Jubilant Pharma Business Overview Table 121. Jubilant Pharma Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Jubilant Pharma Montelukast Drug Product Portfolio Table 123. Jubilant Pharma Recent Development Table 124. Hikma Group Company Information Table 125. Hikma Group Business Overview Table 126. Hikma Group Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Hikma Group Montelukast Drug Product Portfolio Table 128. Hikma Group Recent Development Table 129. Hetero Company Information Table 130. Hetero Business Overview Table 131. Hetero Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Hetero Montelukast Drug Product Portfolio Table 133. Hetero Recent Development Table 134. Glenmark Pharmaceuticals Company Information Table 135. Glenmark Pharmaceuticals Business Overview Table 136. Glenmark Pharmaceuticals Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Glenmark Pharmaceuticals Montelukast Drug Product Portfolio Table 138. Glenmark Pharmaceuticals Recent Development Table 139. Dr. Reddys Laboratories Company Information Table 140. Dr. Reddys Laboratories Business Overview Table 141. Dr. Reddys Laboratories Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Dr. Reddys Laboratories Montelukast Drug Product Portfolio Table 143. Dr. Reddys Laboratories Recent Development Table 144. CSPC Ouyi Pharmaceutical Company Information Table 145. CSPC Ouyi Pharmaceutical Business Overview Table 146. CSPC Ouyi Pharmaceutical Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. CSPC Ouyi Pharmaceutical Montelukast Drug Product Portfolio Table 148. CSPC Ouyi Pharmaceutical Recent Development Table 149. Cipla Company Information Table 150. Cipla Business Overview Table 151. Cipla Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Cipla Montelukast Drug Product Portfolio Table 153. Cipla Recent Development Table 154. Aurobindo Pharma Company Information Table 155. Aurobindo Pharma Business Overview Table 156. Aurobindo Pharma Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Aurobindo Pharma Montelukast Drug Product Portfolio Table 158. Aurobindo Pharma Recent Development Table 159. Apotex Company Information Table 160. Apotex Business Overview Table 161. Apotex Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Apotex Montelukast Drug Product Portfolio Table 163. Apotex Recent Development Table 164. Amneal Pharmaceuticals Company Information Table 165. Amneal Pharmaceuticals Business Overview Table 166. Amneal Pharmaceuticals Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Amneal Pharmaceuticals Montelukast Drug Product Portfolio Table 168. Amneal Pharmaceuticals Recent Development Table 169. Ajanta Pharma Company Information Table 170. Ajanta Pharma Business Overview Table 171. Ajanta Pharma Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Ajanta Pharma Montelukast Drug Product Portfolio Table 173. Ajanta Pharma Recent Development Table 174. Accord Healthcare Company Information Table 175. Accord Healthcare Business Overview Table 176. Accord Healthcare Montelukast Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. Accord Healthcare Montelukast Drug Product Portfolio Table 178. Accord Healthcare Recent Development Table 179. Key Raw Materials Table 180. Raw Materials Key Suppliers Table 181. Montelukast Drug Distributors List Table 182. Montelukast Drug Customers List Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources Table 186. Primary Sources List of Figures Figure 1. Montelukast Drug Product Image Figure 2. Global Montelukast Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Montelukast Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Montelukast Drug Sales (2021-2032) & (W Units) Figure 5. Global Montelukast Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Montelukast Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tablets Image Figure 10. Oral Granules Image Figure 11. Global Montelukast Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Montelukast Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Montelukast Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Montelukast Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Montelukast Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Montelukast Drug Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Drug Store Image Figure 19. Others Image Figure 20. Global Montelukast Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 21. Global Montelukast Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Montelukast Drug Sales Volume Share by Application (2021-2032) Figure 23. Global Montelukast Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Montelukast Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Montelukast Drug Sales Value Share by Application (2021-2032) Figure 26. Global Montelukast Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 27. Global Montelukast Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Montelukast Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Montelukast Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Montelukast Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America Montelukast Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Montelukast Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Montelukast Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Montelukast Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Montelukast Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Montelukast Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America Montelukast Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Montelukast Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Montelukast Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Montelukast Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Montelukast Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Montelukast Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Montelukast Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Montelukast Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Oral Granules
Applications
  • Hospital
  • Drug Store
  • Others
Companies covered
  • Teva
  • Sandoz
  • Merck & Co.
  • Mylan
  • Unimark
  • Unichem Laboratories
  • Torrent Pharmaceuticals
  • Shanghai Anbison Lab
  • Perrigo
  • MACLEODS
  • Lannett Company
  • Jubilant Pharma
  • Hikma Group
  • Hetero
  • Glenmark Pharmaceuticals
  • Dr. Reddys Laboratories
  • CSPC Ouyi Pharmaceutical
  • Cipla
  • Aurobindo Pharma
  • Apotex
  • Amneal Pharmaceuticals
  • Ajanta Pharma
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Montelukast Drug Sales Value (2021-2032)
  4. 1.2.2 Global Montelukast Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Montelukast Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Montelukast Drug Market Dynamics
  1. 2.1 Montelukast Drug Industry Trends
  2. 2.2 Montelukast Drug Industry Drivers
  3. 2.3 Montelukast Drug Industry Opportunities and Challenges
  4. 2.4 Montelukast Drug Industry Restraints
3 Montelukast Drug Market by Company
  1. 3.1 Global Montelukast Drug Company Revenue Ranking in 2025
  2. 3.2 Global Montelukast Drug Revenue by Company (2021-2026)
  3. 3.3 Global Montelukast Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Montelukast Drug Average Price by Company (2021-2026)
  5. 3.5 Global Montelukast Drug Company Ranking (2024-2026)
  6. 3.6 Global Montelukast Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Montelukast Drug Company Product Type and Application
  8. 3.8 Global Montelukast Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Montelukast Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Montelukast Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Montelukast Drug Market by Type
  1. 4.1 Montelukast Drug Type Introduction
  2. 4.1.1 Tablets
  3. 4.1.2 Oral Granules
  4. 4.2 Global Montelukast Drug Sales Volume by Type
  5. 4.2.1 Global Montelukast Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Montelukast Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Montelukast Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Montelukast Drug Sales Value by Type
  9. 4.3.1 Global Montelukast Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Montelukast Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Montelukast Drug Sales Value Share by Type (2021-2032)
5 Montelukast Drug Market by Application
  1. 5.1 Montelukast Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drug Store
  4. 5.1.3 Others
  5. 5.2 Global Montelukast Drug Sales Volume by Application
  6. 5.2.1 Global Montelukast Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Montelukast Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Montelukast Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Montelukast Drug Sales Value by Application
  10. 5.3.1 Global Montelukast Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Montelukast Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Montelukast Drug Sales Value Share by Application (2021-2032)
6 Montelukast Drug Regional Sales and Value Analysis
  1. 6.1 Global Montelukast Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Montelukast Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Montelukast Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Montelukast Drug Sales by Region (2027-2032)
  5. 6.3 Global Montelukast Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Montelukast Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Montelukast Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Montelukast Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Montelukast Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Montelukast Drug Sales Value (2021-2032)
  12. 6.6.2 North America Montelukast Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Montelukast Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Montelukast Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Montelukast Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Montelukast Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Montelukast Drug Sales Value (2021-2032)
  21. 6.9.2 South America Montelukast Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Montelukast Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Montelukast Drug Sales Value Share by Country, 2025 VS 2032
7 Montelukast Drug Country-level Sales and Value Analysis
  1. 7.1 Global Montelukast Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Montelukast Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Montelukast Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Montelukast Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Montelukast Drug Sales by Country (2027-2032)
  6. 7.4 Global Montelukast Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Montelukast Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Montelukast Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Montelukast Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Montelukast Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Montelukast Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Montelukast Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Montelukast Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Montelukast Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Montelukast Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Montelukast Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Montelukast Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Montelukast Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Montelukast Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Montelukast Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Montelukast Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Montelukast Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Montelukast Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Montelukast Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Montelukast Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Montelukast Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Montelukast Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Montelukast Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Montelukast Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Montelukast Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Montelukast Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Montelukast Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Montelukast Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Montelukast Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Montelukast Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Montelukast Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Montelukast Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Montelukast Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Montelukast Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Montelukast Drug Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sandoz
  8. 8.2.1 Sandoz Company Information
  9. 8.2.2 Sandoz Business Overview
  10. 8.2.3 Sandoz Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz Montelukast Drug Product Portfolio
  12. 8.2.5 Sandoz Recent Developments
  13. 8.3 Merck & Co.
  14. 8.3.1 Merck & Co. Company Information
  15. 8.3.2 Merck & Co. Business Overview
  16. 8.3.3 Merck & Co. Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co. Montelukast Drug Product Portfolio
  18. 8.3.5 Merck & Co. Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Montelukast Drug Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Unimark
  26. 8.5.1 Unimark Company Information
  27. 8.5.2 Unimark Business Overview
  28. 8.5.3 Unimark Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Unimark Montelukast Drug Product Portfolio
  30. 8.5.5 Unimark Recent Developments
  31. 8.6 Unichem Laboratories
  32. 8.6.1 Unichem Laboratories Company Information
  33. 8.6.2 Unichem Laboratories Business Overview
  34. 8.6.3 Unichem Laboratories Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Unichem Laboratories Montelukast Drug Product Portfolio
  36. 8.6.5 Unichem Laboratories Recent Developments
  37. 8.7 Torrent Pharmaceuticals
  38. 8.7.1 Torrent Pharmaceuticals Company Information
  39. 8.7.2 Torrent Pharmaceuticals Business Overview
  40. 8.7.3 Torrent Pharmaceuticals Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Torrent Pharmaceuticals Montelukast Drug Product Portfolio
  42. 8.7.5 Torrent Pharmaceuticals Recent Developments
  43. 8.8 Shanghai Anbison Lab
  44. 8.8.1 Shanghai Anbison Lab Company Information
  45. 8.8.2 Shanghai Anbison Lab Business Overview
  46. 8.8.3 Shanghai Anbison Lab Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai Anbison Lab Montelukast Drug Product Portfolio
  48. 8.8.5 Shanghai Anbison Lab Recent Developments
  49. 8.9 Perrigo
  50. 8.9.1 Perrigo Company Information
  51. 8.9.2 Perrigo Business Overview
  52. 8.9.3 Perrigo Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Perrigo Montelukast Drug Product Portfolio
  54. 8.9.5 Perrigo Recent Developments
  55. 8.10 MACLEODS
  56. 8.10.1 MACLEODS Company Information
  57. 8.10.2 MACLEODS Business Overview
  58. 8.10.3 MACLEODS Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 MACLEODS Montelukast Drug Product Portfolio
  60. 8.10.5 MACLEODS Recent Developments
  61. 8.11 Lannett Company
  62. 8.11.1 Lannett Company Company Information
  63. 8.11.2 Lannett Company Business Overview
  64. 8.11.3 Lannett Company Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Lannett Company Montelukast Drug Product Portfolio
  66. 8.11.5 Lannett Company Recent Developments
  67. 8.12 Jubilant Pharma
  68. 8.12.1 Jubilant Pharma Company Information
  69. 8.12.2 Jubilant Pharma Business Overview
  70. 8.12.3 Jubilant Pharma Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Jubilant Pharma Montelukast Drug Product Portfolio
  72. 8.12.5 Jubilant Pharma Recent Developments
  73. 8.13 Hikma Group
  74. 8.13.1 Hikma Group Company Information
  75. 8.13.2 Hikma Group Business Overview
  76. 8.13.3 Hikma Group Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Hikma Group Montelukast Drug Product Portfolio
  78. 8.13.5 Hikma Group Recent Developments
  79. 8.14 Hetero
  80. 8.14.1 Hetero Company Information
  81. 8.14.2 Hetero Business Overview
  82. 8.14.3 Hetero Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Hetero Montelukast Drug Product Portfolio
  84. 8.14.5 Hetero Recent Developments
  85. 8.15 Glenmark Pharmaceuticals
  86. 8.15.1 Glenmark Pharmaceuticals Company Information
  87. 8.15.2 Glenmark Pharmaceuticals Business Overview
  88. 8.15.3 Glenmark Pharmaceuticals Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Glenmark Pharmaceuticals Montelukast Drug Product Portfolio
  90. 8.15.5 Glenmark Pharmaceuticals Recent Developments
  91. 8.16 Dr. Reddys Laboratories
  92. 8.16.1 Dr. Reddys Laboratories Company Information
  93. 8.16.2 Dr. Reddys Laboratories Business Overview
  94. 8.16.3 Dr. Reddys Laboratories Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Dr. Reddys Laboratories Montelukast Drug Product Portfolio
  96. 8.16.5 Dr. Reddys Laboratories Recent Developments
  97. 8.17 CSPC Ouyi Pharmaceutical
  98. 8.17.1 CSPC Ouyi Pharmaceutical Company Information
  99. 8.17.2 CSPC Ouyi Pharmaceutical Business Overview
  100. 8.17.3 CSPC Ouyi Pharmaceutical Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 CSPC Ouyi Pharmaceutical Montelukast Drug Product Portfolio
  102. 8.17.5 CSPC Ouyi Pharmaceutical Recent Developments
  103. 8.18 Cipla
  104. 8.18.1 Cipla Company Information
  105. 8.18.2 Cipla Business Overview
  106. 8.18.3 Cipla Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Cipla Montelukast Drug Product Portfolio
  108. 8.18.5 Cipla Recent Developments
  109. 8.19 Aurobindo Pharma
  110. 8.19.1 Aurobindo Pharma Company Information
  111. 8.19.2 Aurobindo Pharma Business Overview
  112. 8.19.3 Aurobindo Pharma Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Aurobindo Pharma Montelukast Drug Product Portfolio
  114. 8.19.5 Aurobindo Pharma Recent Developments
  115. 8.20 Apotex
  116. 8.20.1 Apotex Company Information
  117. 8.20.2 Apotex Business Overview
  118. 8.20.3 Apotex Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Apotex Montelukast Drug Product Portfolio
  120. 8.20.5 Apotex Recent Developments
  121. 8.21 Amneal Pharmaceuticals
  122. 8.21.1 Amneal Pharmaceuticals Company Information
  123. 8.21.2 Amneal Pharmaceuticals Business Overview
  124. 8.21.3 Amneal Pharmaceuticals Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Amneal Pharmaceuticals Montelukast Drug Product Portfolio
  126. 8.21.5 Amneal Pharmaceuticals Recent Developments
  127. 8.22 Ajanta Pharma
  128. 8.22.1 Ajanta Pharma Company Information
  129. 8.22.2 Ajanta Pharma Business Overview
  130. 8.22.3 Ajanta Pharma Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Ajanta Pharma Montelukast Drug Product Portfolio
  132. 8.22.5 Ajanta Pharma Recent Developments
  133. 8.23 Accord Healthcare
  134. 8.23.1 Accord Healthcare Company Information
  135. 8.23.2 Accord Healthcare Business Overview
  136. 8.23.3 Accord Healthcare Montelukast Drug Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Accord Healthcare Montelukast Drug Product Portfolio
  138. 8.23.5 Accord Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Montelukast Drug Value Chain Analysis
  2. 9.1.1 Montelukast Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Montelukast Drug Sales Mode & Process
  6. 9.2 Montelukast Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Montelukast Drug Distributors
  9. 9.2.3 Montelukast Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst